Win For Axonics As England’s NICE Says Rechargeable Neuromodulation Is Cost-Effective
Executive Summary
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.
You may also be interested in...
FDA Expands Indication For Axonics’ Incontinence System; Medtronic Claims Patent Infringement
The US FDA approved Axonics’ r-SNM sacral neuromodulation system for treating overactive bladder and urinary retention on 14 November. The agency approved the same device for treating chronic fecal incontinence on 9 September. Axonics expects r-SNM to rival Medtronic's InterStim II non-rechargeable sacral neuromodulation system, but Medtronic claims the r-SNM technology infringes on Medtronic’s intellectual property.
Australia Becomes First Country To Regulate Psilocybin & MDMA As Medicines
The Therapeutic Goods Administration said its decision to down-schedule two psychedelic substances to controlled drug status followed extensive public consultation, a report from an independent expert panel, and advice from the Advisory Committee on Medicines Scheduling.
Who Will Join Us? EU Regulators Seek Feedback On Proposed Clinical Trials Discussion Platform
Regulators want to know who is interested in joining their planned multi-stakeholder platform for discussions on how to improve clinical trials in Europe. They are also seeking feedback on which topics should be prioritized for discussion.